Anti-inflammatory and cytoprotective effects of inosine

Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases

Volumn , Issue , 2006, Pages 237-256

  Szabó, Csaba ^a   Gerô, Domokos ^b   Haskó, György ^c  

^a INOTEK CORPORATION   (United States)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84155162129     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (94)

1. Deussen, A., Metabolic flux rates of adenosine in the heart, Naunyn-Schmiedeberg’s Arch. Pharmacol., 362, 351, 2000.
2. Pastor-Anglada, M. et al., Complex regulation of nucleoside transporter expression in epithelial and immune system cells, Mol. Membr. Biol., 18, 81, 2001.
3. Aldrich, M.B., Blackburn, M.R., and Kellems, R.E., The importance of adenosine deaminase for lymphocyte development and function, Biochem. Biophys. Res. Commun., 272, 311, 2000.
4. Ralevic, V. and Burnstock, G., Receptors for purines and pyrimidines, Pharmacol. Rev., 50, 413, 1998.
5. Fredholm, B.B. et al., International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors, Pharmacol. Rev., 53, 527, 2001.
6. 3 adenosine receptors and stimulates mast cell degranulation, J. Clin. Invest., 100, 2849, 1997.
7. Hasko, G. et al., Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock, J. Immunol., 164, 1013, 2000.
8. Tilley, S.L. et al., Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells, J. Clin. Invest., 105, 361, 2000.
9. 2 alpha receptors inhibits mast cell degranulation and mast cell-dependent vasoconstriction, Microcirculation, 7, 129, 2000.
10. 3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis, Mol. Pharmacol., 59, 76, 2001.
11. Fredholm, B.B. et al., Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells, Biochem. Pharmacol., 61, 443, 2001.
12. 3 adenosine receptors for the protective effect of inosine in vivo, Blood, 102, 4472, 2003.
13. 2a receptor ligand binding site, J. Neurochem., 63, 1477, 1994.
14. Souza, L.F. et al., Extracellular inosine modulates ERK 1/2 and p38 phosphorylation in cultured sertoli cells: possible participation in TNF-alpha modulation of ERK 1/2, Life Sci., 2005.
15. Benyon, R.C. et al., The effect of methyltransferase inhibitors on histamine release from human dispersed lung mast cells activated with anti-human IgE and calcium ionophore A23187, Biochem. Pharmacol., 33, 2881, 1984.
16. 3 adenosine receptor, Circ. Res., 78, 627, 1996.
17. Hasko, G., Sitkovsky, M.V., and Szabo, C., Immunomodulatory and neuroprotective effects of inosine, Trends Pharmacol. Sci., 25, 152, 2004.
18. Marton, A. et al., Anti-inflammatory effects of inosine in human monocytes, neutrophils and epithelial cells in vitro, Int. J. Mol. Med., 8, 617, 2001.
19. Ulevitch, R.J., New therapeutic targets revealed through investigations of innate immunity, Crit. Care Med., 29, S8, 2001.
20. Garcia Soriano, F. et al., Inosine improves gut permeability and vascular reactivity in endotoxic shock, Crit. Care Med., 29, 703, 2001.
21. Liaudet, L. et al., Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury, Ann. Surg., 235, 568, 2002.
22. Deitch, E.A., Animal models of sepsis and shock: a review and lessons learned, Shock, 9, 1, 1998.
23. Liaudet, L. et al., Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture, Am. J. Respir. Crit. Care Med., 164, 1213, 2001.
24. Darlington, D.N. and Gann, D.S., Purine nucleosides stimulate Na/K ATPase, and prolong survival in hemorrhagic shock, J. Trauma, 58, 1055, 2005.
25. Lam-Tse, W.K., Lernmark, A., and Drexhage, H.A., Animal models of endocrine/organspecific autoimmune diseases: do they really help us to understand human autoimmunity?, Springer Semin. Immunopathol., 24, 297, 2002.
26. Mabley, J.G. et al., Inosine protects against the development of diabetes in multiplelow- dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes, Mol. Med., 9, 96, 2003.
27. Mabley, J.G. et al., Inosine reduces inflammation and improves survival in a murine model of colitis, Am. J. Physiol. Gastrointest. Liver Physiol., 284, G138, 2003.
28. Mabley, J. et al., Inosine protects against development of collagen-induced arthritis, FASEB J., 18, A495, 2004 (abstract).
29. Yamagiwa, T. et al., Inosine alleviates rat caerulein pancreatitis and pancreatitisassociated lung injury, J. Gastroenterol., 39, 41, 2004.
30. Lohinai, Z., Mabley, J., and Szabo, C., Inosine exerts antiinflammatory effects in a rat model of periodontitis, Acta Phys. Hung., in press, 2005 (abstract).
31. Scott, G.S. et al., Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors, Proc. Natl. Acad. Sci. U.S.A., 99, 16303, 2002.
32. Hooper, D.C. et al., Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis, Proc. Natl. Acad. Sci. U.S.A., 94, 2528, 1997.
33. de Jong, J.W., Verdouw, P.D., and Remme, W.J., Myocardial nucleoside and carbohydrate metabolism and hemodynamics during partial occlusion and reperfusion of pig coronary artery, J. Mol. Cell. Cardiol., 9, 297, 1977.
34. Fox, A.C. et al., Release of nucleosides from canine and human hearts as an index of prior ischemia, Am. J. Cardiol., 43, 52, 1979.
35. Hale, S.L. et al., Alterations in the distribution of high-energy phosphates during ischemia in a canine model of reperfusion-induced ventricular fibrillation, Am. Heart J., 110, 590, 1985.
36. Eklund, T. et al., Interstitial lactate, inosine and hypoxanthine in rat kidney during normothermic ischaemia and recirculation, Acta Physiol. Scand., 143, 279, 1991.
37. Czarnecki, W. and Herbaczynska-Cedro, K., The influence of inosine on the size of myocardial ischaemia and myocardial metabolism in the pig, Clin. Physiol., 2, 189, 1982.
38. DeWitt, D.F., Jochim, K.E., and Behrendt, D.M., Nucleotide degradation and functional impairment during cardioplegia: amelioration by inosine, Circulation, 67, 171, 1983.
39. Aussedat, J., Verdys, M., and Rossi, A., Adenine nucleotide synthesis from inosine during normoxia and after ischaemia in the isolated perfused rat heart, Can. J. Physiol. Pharmacol., 63, 1159, 1985.
40. Hagberg, H. et al., Blockade of N-methyl-D-aspartate-sensitive acidic amino acid receptors inhibits ischemia-induced accumulation of purine catabolites in the rat striatum, Neurosci. Lett., 68, 311, 1986.
41. Wakai, A. et al., Inosine attenuates tourniquet-induced skeletal muscle reperfusion injury, J. Surg. Res., 99, 311, 2001.
42. Dowdall, J.F., Winter, D.C., and Bouchier-Hayes, D.J., Inosine modulates gut barrier dysfunction and end organ damage in a model of ischemia-reperfusion injury, J. Surg. Res., 108, 61, 2002.
43. Yao, Y.M. et al., The potential etiologic role of tumor necrosis factor in mediating multiple organ dysfunction in rats following intestinal ischemia-reperfusion injury, Resuscitation, 29, 157, 1995.
44. Seekamp, A. et al., Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury, Am. J. Pathol., 143, 453, 1993.
45. Shen, H. et al., Inosine reduces ischemic brain injury in rats, Stroke, 36, 654, 2005.
46. Buckley, S. et al., In vivo inosine protects alveolar epithelial type 2 cells against hyperoxia-induced DNA damage through MAP kinase signaling, Am. J. Physiol. Lung Cell. Mol. Physiol., 288, L569, 2005.
47. Stone, T.W., Purines and neuroprotection, Adv. Exp. Med. Biol., 513, 249, 2002.
48. Haun, S.E. et al., Inosine mediates the protective effect of adenosine in rat astrocyte cultures subjected to combined glucose-oxygen deprivation, J. Neurochem., 67, 2051, 1996.
49. Jurkowitz, M.S. et al., Adenosine, inosine, and guanosine protect glial cells during glucose deprivation and mitochondrial inhibition: correlation between protection and ATP preservation, J. Neurochem., 71, 535, 1998.
50. Litsky, M.L. et al., Inosine and guanosine preserve neuronal and glial cell viability in mouse spinal cord cultures during chemical hypoxia, Brain Res., 821, 426, 1999.
51. Benowitz, L.I. et al., Axon outgrowth is regulated by an intracellular purine-sensitive mechanism in retinal ganglion cells, J. Biol. Chem., 273, 29626, 1998.
52. Petrausch, B. et al., A purine-sensitive pathway regulates multiple genes involved in axon regeneration in goldfish retinal ganglion cells, J. Neurosci., 20, 8031, 2000.
53. Benowitz, L.I. et al., Inosine stimulates extensive axon collateral growth in the rat corticospinal tract after injury, Proc. Natl. Acad. Sci. U.S.A., 96, 13486, 1999.
54. Chen, P. et al., Inosine induces axonal rewiring and improves behavioral outcome after stroke, Proc. Natl. Acad. Sci. U.S.A., 99, 9031, 2002.
55. Ohta, A. and Sitkovsky, M., Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage, Nature, 414, 916, 2001.
56. Hasko, G. et al., Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice, J. Immunol., 157, 4634, 1996.
57. Szabo, C. et. al., Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists, Br. J. Pharmacol., 125, 379, 1998.
58. 2a receptor-dependent and independent mechanisms, FASEB J., 14, 2065, 2000.
59. Salvatore, C.A. et al., Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells, J. Biol. Chem., 275, 4429, 2000.
60. 3 receptors, Neuroscience, 114, 523, 2002.
61. 3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68, Arthritis Rheum., 48, 240, 2003.
62. 3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis, Eur. J. Pharmacol., 466, 323, 2003.
63. Ames, B.N. et al., Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis, Proc. Natl. Acad. Sci. U.S.A., 78, 6858, 1981.
64. Kooy, N.W. et al., Peroxynitrite-mediated oxidation of dihydrorhodamine 123, Free Radic. Biol. Med., 16, 149, 1994.
65. Szabo, C. and Salzman, A.L., Endogenous peroxynitrite is involved in the inhibition of mitochondrial respiration in immuno-stimulated J774.2 macrophages, Biochem. Biophys. Res. Commun., 209, 739, 1995.
66. Hooper, D.C. et al., Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis, Proc. Natl. Acad. Sci. U.S.A., 95, 675, 1998.
67. Drulovic, J. et al., Uric acid levels in sera from patients with multiple sclerosis, J. Neurol., 248, 121, 2001.
68. Spitsin, S. et al., Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease, Mult. Scler., 7, 313, 2001.
69. Gius, D. et al., Intracellular oxidation/reduction status in the regulation of transcription factors NF-kappaB and AP-1, Toxicol. Lett., 106, 93, 1999.
70. Haddad, J.J., Oxygen-sensitive pro-inflammatory cytokines, apoptosis signaling and redox-responsive transcription factors in development and pathophysiology, Cytokines Cell. Mol. Ther., 7, 1, 2002.
71. Virag, L. and Szabo, C., The therapeutic potential of poly(ADP-ribose) polymerase inhibitors, Pharmacol. Rev., 54, 375, 2002.
72. Jagtap, P. and Szabo, C., Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors, Nat. Rev. Drug Discov., 4, 421, 2005.
73. Virag, L. and Szabo, C., Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death, FASEB J., 15, 99, 2001.
74. 2+-transients and actin polymerization in immature human dendritic cells via a pertussis toxin-sensitive mechanism independent of adenosine receptors, J. Cell. Physiol., 199, 149, 2004.
75. Reid, P.G. et al., Intravenous infusion of adenosine but not inosine stimulates respiration in man, Br. J. Clin. Pharmacol., 23, 331, 1987.
76. Williams, M.H. et al., Effect of inosine supplementation on 3-mile treadmill run performance and VO2 peak, Med. Sci. Sports Exerc., 22, 517, 1990.
77. McNaughton, L., Dalton, B., and Tarr, J., Inosine supplementation has no effect on aerobic or anaerobic cycling performance, Int. J. Sport Nutr., 9, 333, 1999.
78. Linquette, M. et al., Clinical trial of inosine for cardiovascular disorders and in surgical resuscitation, Lille Med., 12, Suppl. 265, 1967.
79. Kipshidze, N.N. et al., Indications for the use of inosine in myocardial infarct (a clinical and experimental study), Kardiologiia, 18, 18, 1978.
80. Golikov, A.P. et al., Stimulation of reparative processes in myocardial infarction:comparative evaluation of the effects of piracetam and inosine, Kardiologiia, 28, 46, 1988.
81. Becker, H. et al., Therapy of rheumatic diseases with inosiplex, Immun. Infekt., 14, 93, 1986.
82. Maciejek, Z. and Niezgodzinska-Maciejek, A., Prospective assessment of combined treatment with high doses of intravenous methylprednisolone and long term administration of isoprinosine in multiple sclerosis patients, Neurol. Neurochir. Pol., 27, 321, 1993.
83. Anlar, B. et al., The effect of inosiplex in subacute sclerosing panencephalitis: a clinical and laboratory study, Eur. Neurol., 34, 44, 1994.
84. Gascon, G.G., Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE):international multicenter study, J. Child Neurol., 18, 819, 2003.
85. Barasoain, I. et al., Isoprinosine restores in vitro T lymphocyte functions of cyclophosphamide immunosuppressed mice, Int. J. Immunopharmacol., 9, 489, 1987.
86. Schmutzler, W., Neukirch, B., and Ziesche, R., Study of the antiallergic component of inosine pranobex (Inosiplex, Isoprinosine), Int. Arch. Allergy Appl. Immunol., 88, 244, 1989.
87. Loseva, M.I., Purtova, L.A., and Gavalova, R.F., Angiotensin converting enzyme inhibitor enalapril in the treatment of endomyocardial fibrosis in patients with lymphogranulomatosis subjected to radio- and chemotherapy, Kardiologiia, 42, 48, 2002.
88. Cheng, Y. and Jiang, D.H., Therapeutic effect of inosine in Tourette syndrome and its possible mechanism of action, Zhonghua Shen Jing Jing Shen Ke Za Zhi, 23, 90, 126, 1990.
89. Wickham, J.E. et al., Inosine: clinical results of ischaemic renal surgery, Br. J. Urol., 50, 465, 1978.
90. Mentzer, R.M., Jr. et al., Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery, Am. J. Cardiol., 79, 38, 1997.
91. Dragan, I. et al., Studies regarding some effects of inosine in elite weightlifters, Rom. J. Physiol., 30, 47, 1993.
92. Starling, R.D. et al., Effect of inosine supplementation on aerobic and anaerobic cycling performance, Med. Sci. Sports Exerc., 28, 1193, 1996.
93. Gil, A. et al., Effect of dietary nucleotides on the plasma fatty acids in at-term neonates, Hum. Nutr. Clin. Nutr., 40, 185, 1986.
94. Axelsson, I. et al., The influence of dietary nucleotides on erythrocyte membrane fatty acids and plasma lipids in preterm infants, Acta Paediatr., 86, 539, 1997.